植物新藥研發-新藥價值

Economists estimate that for the past 15 years, the prolonged life span in industrialized  countries should be attributed to New Drug. In the U.S. alone, it is estimated that economic gains from medical innovation are as high as $ 500 billion annually.Development of new drugs is costly and risky. Cost estimations for developing a new drug vary greatly; it can range from $ 800 million to $ 2 billion US dollars. In fact, even if the estimation seems too high, it may actually be lower than the actual costs. For example, Pfizer recently announced that the investment for merely one new drug in phase III trial is up to $ 800 million US dollars.

There are 6 important processes need to be fulfilled before developing a new drug and bring it to market. Even large amount of budget needs to be spent to observe the efficacy of the drug in the post-market stage. Conservatively, it is estimated that around $300 million to $ 600 million US dollars need to be invested. The cost can be up to 1 billion US dollars if the RD period is prolonged; plus an average 10 years of developing period. But the valuable point of the development of a new drug is the high profits that it can generate after entering the market. The world’s top 10 best-selling drugs generate annual sales of more than $ 6 billion US dollars. This shows that at least 10 times of return on investment (ROI) can be achieved if the drug is successfully developed and the topic is correctly chosen. According to estimations from Morgan Stanley, the average developing value of a new drug at the preclinical stage is $24 million US dollars. Once it enters clinical trial stage, the value jumps right to $104 million US dollars. When it enters phase III clinical trial, the value increases to $436 million US dollars. The value is $1,008 million and $1,594 million US dollars respectively if it can reach NDA stage and enter the market.

pipeline

therapeutic area code name indication phase preclin IND I IND II IND III